Puma Biotechnology Inc Common Stock (PBYI)
Stock · NASDAQ · Health Care
$9.83as of 10/16/2026
Price chart
Active signals
PBYI Signal Track Record
How signals performed across all stocks →What PBYI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +4.9% | 59% | August 7, 2026 |
| Bollinger Band Breakout | 30 | +5.5% | 67% | October 9, 2026 |
| Bollinger Band Breakdown | 17 | +5.2% | 59% | May 11, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +4.5% | 69% | July 30, 2025 |
| Any 20-session window (baseline) | +3.3% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The c…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 179
- Website
- www.pumabiotechnology.com/
Fundamentals
- 1-day range
- $9.85$10.51
- Market cap
- $413.30M
- P/E (trailing)
- 20.62
- P/E (forward)
- 28.13
- EPS (trailing)
- $0.52
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 318.6K
How Puma Biotechnology Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Puma Biotechnology Inc Common Stock Competitors
Chosen by industry and closest market cap.
- PBYIPuma Biotechnology Inc Common Stock$9.83▼ 6.56%Market cap $413.30MP/E 20.62$4.58$10.5
- KMDAKamada Ltd. Ordinary Shares$7.76▼ 0.89%Market cap $411.88MP/E 20.30$6.55$9.35
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PBYI Puma Biotechnology Inc Common Stock | $413.30M | 20.62 | $9.83 | ▼ 6.56% | $4.58$10.5 |
| KMDA Kamada Ltd. Ordinary Shares | $411.88M | 20.30 | $7.76 | ▼ 0.89% | $6.55$9.35 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga · 10/12/2026
- Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/5/2026
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsYahoo · 9/18/2026
- Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung CancerYahoo · 9/17/2026
- Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung CancerBenzinga · 9/17/2026
Insider Activity
Insider Actions →- Troy Edward Wilson · September 14, 2026 · Sale5.0K @ $9.1
- Cesano Alessandra · September 14, 2026 · Option Exercise50.0K @ $2.93
- Cesano Alessandra · September 14, 2026 · Sale62.1K @ $9.12
- HUNT DOUGLAS M · July 6, 2026 · Sale8.5K @ $8.26
- NOUGUES MAXIMO F · July 6, 2026 · Sale9.4K @ $8.26
- AUERBACH ALAN H · July 6, 2026 · Sale44.1K @ $8.26
- Troy Edward Wilson · June 12, 2026 · Sale10.8K @ $7.2
- Brian M. Stuglik · June 12, 2026 · Sale8.1K @ $7.2
- Senderowicz Adrian · June 12, 2026 · Sale27.0K @ $7.2
- Dorval Allison · June 12, 2026 · Sale11.6K @ $7.2
- MOYES JAY M · June 12, 2026 · Sale22.0K @ $7.22
- Dorval Allison · June 11, 2026 · Grant27.0K
- Cesano Alessandra · June 11, 2026 · Grant27.0K
- MILLER MICHAEL PATRICK · June 11, 2026 · Grant27.0K
- MOYES JAY M · June 11, 2026 · Grant27.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 35.74M
- Total value held
- $207.30M
- Institutional holders
- 152
- Unknown4.13M
- Unknown3.60M
- Unknown2.04M
- Unknown1.94M
- Unknown1.92M
- Unknown1.82M
- Unknown1.48M
- Unknown1.44M
- Unknown1.18M
- Unknown1.14M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4)
Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4). Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.